Challenges and uncertainty in treatments for COVID-19 patients during the early stage of the pandemic in Mexico.

Gilberto González-Arroyo, BS, MS[1,2], Salvador Gómez-García, MD, MS[3], Anel Gómez-García, PhD[4], Mario F. Rodriguez-Moran, MD[1], Maricela García-Arreola, MD[5], Karla Guadalupe López-López, MD, MS[3], Tonatihu Ortiz-Castillo, MD, MS[3], Noga Or-Geva, PhD[6], Sonia Moreno-Grau, PhD[2,7], Carlos D. Bustamante, PhD[2,7,8], Cleto Álvarez-Aguilar, MD, MS[1,9,*], Arturo López-Pineda, PhD[1,2,*]

1. Amphora Health, Morelia, Michoacán, México.

2. Galatea Bio Inc., Miami, Florida, USA.

3. Decentralized Administrative Operation Body, Mexican Institute for Social Security (IMSS), Monterrey, Nuevo Leon, México.

4. Biomedical Research Center of Michoacan, Mexican Institute for Social Security (IMSS), Morelia, Michoacan, México.

5. Decentralized Administrative Operation Body, Mexican Institute for Social Security (IMSS), Morelia, Michoacan, México.

6. Department of Neurology, Stanford University, Stanford, California, USA.

7. Department of Biomedical Data Science, Stanford University, Stanford, California, USA

8. Chan Zuckerberg Biohub, San Francisco, California, USA.

9. Faculty of Medicine. Michoacan University of Saint Nicholas of Hidalgo (UMSNH), Morelia, Michoacan, México.

*Corresponding author

Address correspondence to:

Dr. Arturo Lopez Pineda (arturo@amphorahealth.com)

Amphora Health

Batallón Independencia 80, Chapultepec Norte 58260, Morelia, México.

Phone: +52 443 304 6300

Abstract

Objective: To analyze the treatment outcomes for COVID-19 during the early stages of the pandemic at the Mexican Institute of Social Security.

Material and Methods: In this retrospective observational study, we investigated 130,216 patients with COVID-19 treated in two Mexican states during 2020. A competing risk analysis was performed using death and recovery as possible outcomes, followed by a cox-regression and Kaplan-Meier analysis. Additionally, machine learning models were built to predict the outcomes at fixed times.

Results: Higher prevalence of obesity, diabetes, and heart disease comorbidities were found, which is consistent with Mexico's epidemiological profile. Mortality occurred around 15-20 days from the start of symptoms. Patients undertaking cephalosporin in combination with neuraminidase inhibitors (NAIs) had the worst survival rates, while patients undertaking adamantane, fluoroquinolone, or penicillin had the best survival rates.

Conclusions: Our findings recommend against using specific treatment combinations, and should help improve the country's clinical guidelines.

Keywords: Coronavirus Infections, Anti-Bacterial Agents, Antiviral Agents, Pragmatic Clinical Trials as Topic, Machine Learning, Mexico

1. Introduction

The clinical and epidemiological characteristics of patients with COVID-19 have been well described (1), showing that SARS-Cov-2 infection can vary from mild infection without clinical manifestations, to severe infections and even fatal pneumonias, associated with admission to intensive care units and high mortality worldwide (2). The clinical manifestations include fever, cough, headache, sputum, dyspnea, nasal congestion, fatigue, diarrhea, anosmia and ageusia (3), among others associated with long-term effects (4).

The Centers for Disease Control and Prevention (CDC) in its Coronavirus Disease 2019 (COVID-19) report identified some risk to develop severe forms of the disease when the patient presents asthma, chronic obstructive lung disease, diabetes, severe heart disease, chronic kidney disease (CKD), severe obesity, age older than 65 years, immunocompromised people, liver disease, among others, and gives a series of recommendations for its prevention and protection (5). In the early days of the pandemic in March 2020, initial reports suggested that hypertension, diabetes, and cardiovascular disease were the most common comorbidities in affected patients, and case fatality rates tend to be higher in these individuals (6,7).

Currently, the management of COVID-19 has focused on controlling the source of infection through social isolation, use of personal protection precautions to reduce the risk of transmission; and early diagnosis, isolation, and supportive treatments for affected patients (8). Among the drugs used to combat COVID-19 infection, there are different alternatives that were administered due to their ability to interfere with the mechanisms of entry, virus replication and/or the host's immunopathological response. For example, because IL-6 can play an important role in the fight against COVID-19 infection, due to its pleiotropic role in the entire immune system, the addition

of azithromycin has been proposed as a treatment to reduce the storm of cytokines caused by COVID-19 virus infection (9). The apparent mechanism of action is due to the immunomodulatory activity of azithromycin by blocking IL-6 and TNF-alpha.

The pandemic dimensions of SARS-CoV-2 (10), and the emergence of new strains (11) has already affected more than 566.9 million people in the world and is the cause of more than 6.3 million deaths in the world until 26 July, 2022 (12). In particular, the case fatality rate observed in Mexico is among the highest worldwide (7.6% vs 2.1% worldwide); in recent information in the Americas, the fatality rate remains high in Mexico, only surpassed by Peru (5.9% vs 4.9%) (13). On the other hand, the vaccination program was announced in December 2020 by the country's officials (12); according to the latest reports, the Ministry of Health reported that 83% of the adult population in Mexico has at least one vaccine against COVID-19. Nuevo León and Michoacán have 70% coverage. Mexico's vaccination plan by December 2020, estimated a slow immunization coverage of 3% of the population receiving at least one shot of the available vaccines for the country (14).

At the moment, there are promising drugs for effective treatment of severe forms of the COVID-19 disease. The emergence of novel strains [13] creates uncertainty about the best way to treat these patients. Following guidance from the Pan American Health Organization (PAHO), government officials in Mexico published interim management guidelines based on little known evidence worldwide. The first guideline was published on April 7, 2020, where the use of hydroxychloroquine, azithromycin, steroid, human immunoglobulin, interferon beta b1, IL-6 inhibitor and JAK inhibitor was suggested prior to clinical evaluation (15); On June 25, 2020, the guideline was updated to focus on evaluating the use of complementary therapies such as convalescent plasma, monoclonal antibodies (tocilizumab), steroids (methylprednisolone or

dexamethasone), human immunoglobulin, protein-kinase inhibitors (16). Subsequently, the guideline was updated again on September 25, 2020, where the use of these therapies was suggested under research protocols and to support the management of comorbidities (17). Studies using hydroxychloroquine did not observe beneficial prophylactic effects (18), nor in hospitalized patients with positive SARS-Cov-2 COVID-19 infection hospitalized using hydroxychloroquine alone (19), or in combination (20), no improvement was observed or less time in hospitalizations. Similar results were obtained with the use of convalescent plasma in patients with severe pneumonia secondary to SARS-CoV-2 COVID-19 (21). Other treatments under experimentation include neutralizing antibodies (22) and the use of B-1A cells (23) as a therapeutic potential in SARS-CoV-2 COVID-19 patients; however, additional studies are required to verify its effectiveness and accessibility.

The information contained in the guidelines represents a compilation of the evidence that has emerged in relation to the SARS-CoV-2 COVID-19 pandemic, and it is known by the health authorities and professionals that the information is evolving rapidly. Therefore, health professionals are always advised to use their best clinical judgment when considering the individual patient characteristics, signs and symptoms. In real-world practice, this translates into a large spectrum of potential therapies and combinations that are being used. Evaluating these treatments is of critical importance moving forward to establish the best path forward in the pandemic.

2. Materials and Methods

Study design

This was a retrospective electronic cohort study to analyze the effect of real-world treatments in COVID-19 patients seen at the Mexican Institute for Social Security (*Instituto Mexicano del Seguro Social*, IMSS), the largest healthcare provider in Mexico. The patients were seen at IMSS facilities between March 1st, 2020, and March 1st, 2021 in two states, Michoacan (West) and Nuevo Leon (North). IMSS employs a National Biosurveillance System for Infectious Diseases (*Sistema Nacional de Vigilancia Epidemiológica*, SINOLAVE), which collects relevant information about patients, including demographics, initial symptoms, comorbidities, testing procedures and results, initial medication intake, mortality, and discharge.

Our study has two components, first, we aimed to understand the various treatment patterns used to treat COVID-19 patients, evaluating their performance with mortality as the main outcome and recovery as a secondary outcome taking the latter as the situation when the patient is no longer ill or is discharged because their symptoms improved. Secondly, we then build two machine learning (ML) models to predict the mortality or recovery of a patient given the available data at a given time point of disease progression (10, 20, and 30 days after admission).

A diagram of our study design is shown in Figure 1. Our analysis was run using the R programming language with multiple libraries, which are displayed in a public repository (https://github.com/AmphoraHealth/covid19). Institutional Review Board (IRB) approval was obtained by IMSS National Bioethics Committee and IMSS National Research Committee,

under protocol numbers R-2021-1912-014, R-2020-785-058. The STROBE statement (24) is provided in Supplementary Material A.



Data Sources

SINOLAVE was originally developed for the influenza pandemic of 2009, and it has been quickly evolving to include new variables that are specific to COVID-19, while keeping all those that are also relevant for influenza. De-identification was done by co-author SGG, using the linkage method. Name, last names, and Social Security Number (SSN) were used. All other co-authors did not have access to identifiable information. We filtered the data to select the COVID-19 patients only, which were diagnosed either by a PCR test or by rapid antigen testing.

The database includes information about comorbidities, initial symptoms and drugs taken, also the dates of start of the clinical picture, admission, and discharge. Medication prescription is recorded in SINOLAVE in three categories: antibiotics, antivirals, and antipyretics. We used the first two categories only, since almost all patients were taking some form of antipyretic, most frequently paracetamol. The information is structured and registered at each site using structured vocabulary. All drugs are reported in categories described in Supplementary Material B. All missing data were considered to be missing at random (MAR), which is a reasonable assumption for observational studies and the potential loss of follow-up for a variety of reasons.

Statistical analysis

We calculated the cohort's baseline characteristics for the COVID-19 positive patients, including those with antibiotic and antiviral prescriptions. We created a frequency table from the reported treatments in the database, including combinations of antibiotics and antivirals (See Supplementary Material B). The treatments (alone or in combination) included in the subsequent analyses were those that had at least 100 patients taking them. Time zero for these analyses was the start day of the clinical symptoms.

Following guidance from McCaw et al. (25) we did a competing risk analysis since the classical Kaplan-Meier analysis and Cox proportional hazard model are not appropriate when dealing with two competing outcomes. Since the patients who die cannot recover, then we are in a competing risk situation. To address this, we use the cumulative incidence functions (CIF) (26,27).

We used the CIF approach to compare the two outcomes of death and recovery stratifying by each type of treatment in the database which was taken by 100 patients or more. The Kaplan-Meier and cox proportional hazard model methods are also included for reference in Supplementary Material C. The

Kaplan-Meier was used in both cases, and to reduce bias in the analysis we stratified the database using six variables (age group, sex, obesity, diabetes, hypertension and pneumonia). A Cox proportional hazard model was built using the following covariates: age group, sex, hospitalization status, initial symptoms and comorbidities. The odds ratio was calculated by adjusting with the same variables. To address potential sources of bias, we stratified the dataset by the most common comorbidities (i.e. diabetes, obesity, hypertension, coronary heart disease, and pneumonia), and we also performed a time-window-based study to minimize potential time-related biases (see Supplementary Material B).

Predictions of mortality and recovery

We implemented two classical machine learning models to predict mortality and recovery at fixed points in time. We used a logistic regression model and a random forest model to predict the outcome of the patient (death or recovery) at 10, 20, and 30 days after the start of the clinical picture (day zero). We evaluated these classification tasks using the area under the receiver operating characteristic (AUC) with a 95% confidence interval (CI). The brier skill score (28) was used to test the calibration of these models. It provides an index between -1 (not calibrated) and +1 (calibrated).

3. Results

The dataset consisted of 130,216 COVID-19 patients with a positive real-time polymerase chain reaction (RT-PCR) test of SARS-CoV-2 (97%) or by clinical diagnosis of COVID-19 (3%). We encountered a small number of duplicates in the data which were removed from the analysis. Table 1 summarizes the baseline characteristics, comorbidities and outcomes for these patients.

Table 1. Baseline characteristics. Sex, Age, Comorbidities, Complications, and Mortality are shown for the main cohort and subgroups.

	All Covid+ patients	**Patients taking antivirals AND/OR antibiotics**	**Patients taking antivirals AND antibiotics**
N	130,216 (100%)	5,575 (100%)	955 (100%)
Sex			
Female	66,445 (51%)	2,495 (45%)	380 (40%)
Male	63,771 (49%)	3,080 (55%)	575 (60%)
Age			
< 20	6,654 (5%)	114 (2%)	5 (<1%)
[20, 40)	60,611 (47%)	1,488 (27%)	131 (14%)
[40, 60)	43,537 (33%)	2,027 (36%)	360 (38%)
> 60	19,414(15%)	1,946 (34%)	459 (48%)
Comorbidities			
Hypertension | Obesity | Diabetes | Cardiovascular	36,808 (28%)	2,949 (53%)	635 (66%)
COPD | Asthma | Smoking History	10,509 (8%)	625 (11%)	94 (10%)
Renal failure | Chronic hepatic disease	2,464 (2%)	300 (5%)	50 (5%)
Immunosuppression | HIV | TB | Cancer	1,746 (1%)	128 (2%)	24 (3%)
Neurological	159 (<1%)	11 (<1%)	2 (<1%)
Complications			
Pneumonia	5,409 (4%)	2,128 (38%)	429 (45%)
Death events	11,132 (9%)	1,724 (31%)	461 (48%)

Out of these patients, only 2,746 were taking an antiviral and/or an antibiotic drug. Figure S1 of Supplementary material B shows the antibiotics and antivirals prescribed to this population (alone or in combination). Fluoroquinolones were the largest group of antibiotics prescribed, while neuraminidase inhibitors (NAIs) were the most frequent antivirals. Figure 2 shows the odds ratio from the demographic and symptoms variables (panel A) and from the treatments

(panel B), using mortality as the endpoint. We highlighted those covariates with a more significant p-value.



Figure 2. Forest plot: A) Symptoms, age and sex, B) Type of treatment. Most statistically significant variables in each method were highlighted.

The competing risk analysis of survival and recovery is shown in Figures 3. In the supplementary material, we included a separate analysis using the Kaplan-Meier curves and stratifying by different cofactors (hypertension, age groups, diabetes, sex) and all of these analyses led to the same conclusion. We found out that the use of neuraminidase inhibitors (NAIs) in combination with Cephalosporins showed a considerably lower survival and recovery rate compared to the other treatment patterns. Meanwhile, the use of penicillin has the same or better survival and recovery than those patients not taking any antibiotic or antiviral.



Figure 3. Cumulative Incidences Functions for Mortality and Recovery across the different combinations of treatments. Notice that the only time that the curve of mortality surpasses the curve of recovery is in the case of the combination of cephalosporins with NAIs.

Contrasting with logistic regression (LR) having an average AUC of 0.85 versus the random forest (RF) with an average AUC of 0.92 the random forest model showed good performance when predicting mortality as it is shown in Table 2. The prediction accuracy improved while we relaxed the time window used (i.e., 10, 20, 30 days). All mortality models were calibrated (BSS larger than 0). In contrast, our models had a lower prediction power when predicting recovery in the same cohort, with LR achieving an average AUC of 0.69, and RF with an average AUC of 0.79. The variables used for this prediction task consisted of the initial symptoms, comorbidities and type of treatment; the full list of variables can be consulted in Supplementary Material B. Lower prediction scores in the case of recovery can be explained by the fact that these patients tend to be censored more frequently. So the prediction of this becomes a harder task.

Table 2. AUROC curves. The area under the receiver operating characteristic (AUROC), the 95% confidence intervals (C.I.) and the Brier Skill Score (BSS) for each case is shown.

Classification task	**Logistic regression**			**Random forest**		
Mortality	**AUC**	**95% CI**	**BSS**	**AUC**	**95% CI**	**BSS**
Death within 10 days	0.83	0.83-0.84	0.09	0.91	0.91-0.92	0.30
Death within 20 days	0.85	0.85-0.85	0.20	0.91	0.91-0.92	0.38
Death within 30 days	0.86	0.85-0.86	0.23	0.92	0.91-0.92	0.40
Recovery	**AUC**	**95% CI**	**BSS**	**AUC**	**95% CI**	**BSS**
Recovered within 10 days	0.57	0.57-0.58	-0.01	0.77	0.77-0.78	0.15
Recovered within 20 days	0.66	0.65-0.66	0.08	0.77	0.76-0.77	0.21
Recovered within 30 days	0.69	0.68-0.69	0.10	0.79	0.79-0.79	0.24

4. Discussion

In this study, in patients with COVID-19, we found a direct association of the severity of the disease with chronic disorders such as diabetes, hypertension, obesity, neoplasms, autoimmune diseases and CKD; the signs and symptoms that best predict the disease were identified, also it was found that patients who received adamantane, fluoroquinolone or penicillin as a treatment for SARS-COV-2 infection presented better survival probability, while those who received cephalosporins alone or associated with neuraminidase inhibitors show the worst survival rates.

The COVID-19 infection very rapidly reached pandemic conditions (29) during 2021 and continues to the present time. Several studies have associated chronic diseases such as obesity, diabetes, hypertension, and CKD, among others (30–32) with the development of severe forms of COVID-19 infection, including pneumonia. Mexico ranks third worldwide in deaths attributed to COVID-19 infection and with a high prevalence of these diseases, including CKD (33); therefore, strict control of these conditions is necessary in patients with COVID-19 infection in Mexico and the world.

Regarding access to medicines in the IMSS and treatment policies available to IMSS doctors, these evolved rapidly during the pandemic emergency. As mentioned in the Introduction section, the guidance offered by the Ministry of Health (MoH) was quickly adapted to the global knowledge available at the time. Symptomatic patients with cough, fever, dyspnea or headache were promptly followed up for further investigation including PCR or antigen testing and other laboratory tests. However, due to the limited resources available in a public health system, access to investigational medicinal products from clinical trials was limited. Also, it was unclear at the time what effect any drug or treatment would have had on this new virus. However, the

beneficial effect observed in the survival rate in patients who received adamantane, fluoroquinolone, or penicillin is striking. Special mention is the development of vaccines. Although the vaccination program officially started in January 2021 in Mexico with health workers, the effects of this vaccination program were not observed in our data (March 2021 cutoff).

Regarding the relevant cofactors affecting survival in the present study, we observed that medication patterns differed when different scenarios (e.g., diabetes, hypertension, age, gender) were considered, even when the treatments studied had no known contraindications for the subgroups of the population investigated. The impact of medication on survival outcomes is complex in a real-life setting. Various cofactors could influence it, and various reasons could explain these findings. First, the impact of preexisting comorbidities on the response to infection and target treatment should be considered. Age and age-related diseases, including type 2 diabetes, obesity, and cardiometabolic diseases, are well-known risk factors for the severity of COVID-19 (34–36). These conditions are associated with a chronic inflammatory state (37) and reduced innate and adaptive immune responses (38,39). In fact, these population subgroups have also been associated with decreased influenza virus survival (40). Thus, the patient's medical history, as well as the intrinsic individual variability in the response to medication, or the pharmacogenomic profile, are relevant cofactors that influence individual medication patterns. Furthermore, patients with multiple comorbid conditions may be taking multiple medications, that is, they may have higher rates of polypharmacy. The potential effect of drug-drug interactions (DDIs), how DDIs present clinically, and their direct or indirect effect on COVID-19 outcomes should be considered. Although the underlying biological mechanism triggering these differences in the context of COVID-19 remains largely unknown, in the near future, the

integration of these different layers of information should promote better clinical management of COVID-19 patients. On the other hand, the Mexican public health authorities recently updated the clinical guideline for the treatment of COVID-19, including new antiviral drugs approved by the U.S. Food and Drug Administration (FDA) at the end of 2021 (19,20). These drugs were molnupiravir for adults with a positive test result and with a high risk of developing severe forms of the disease, and paxlovid for the treatment of mild-to-moderate cases in adults and pediatric patients. Moreover, the widespread adoption of these new antivirals is not entirely clear despite being oral drugs for outpatient use, as they are more accessible than drugs administered intravenously (remdesivir, sotrovimab), which require hospital monitoring or are high-cost drugs (43).

On the electronic healthcare system. This study was only possible due to the digitization of SINOLAVE, an IMSS database that was developed during the 2009 Influenza pandemic and later on refurbished to serve the information needs of the 2019 COVID-19 pandemic. Furthermore, the emergence of virtual randomized clinical trials has shown the value to accelerate results and provide informed guidance to patients (44). The digitization of electronic health records is possible and should be an overall strategy in resource-constrained settings to provide a data-driven approach to public health concerns (45). Machine learning models and data science can be effectively applied to these settings augmenting the capabilities of the healthcare system.

On the prediction of mortality and recovery. The positive score while predicting mortality suggests that the variables used by the model explain with satisfactory confidence the outcome of the patient at 30 days from the onset of symptoms. On the other hand, the recovery prediction was not as good, this suggests that the time to recovery could be driven by other factors.

Limitations. This study has several limitations. One limitation is having obtained the information from the SINOLAVE registry. As previously mentioned, the SINOLAVE record was originally structured to generate information on other viral diseases, so it has been adapted to generate information related to COVID-19, including several pharmacological treatments, for the specific purpose of studying the effect of COVID-19 treatments; therefore, other drugs not listed in the registry cannot be analyzed and can be possible confounding factors. Also, the chaotic environment in the pandemic could have affected the quality ingestion of the data in the registry, many rushes were made during the early stages of the pandemic. Another limitation is the short study period used in our study, so the late post-COVID clinical manifestations are unknown. A third limitation is that the study period was set before the vaccination of the general population, so the current treatment conditions may be different.

Conclusion. We observed that the use of the combination of NAIs and cephalosporins as a treatment for COVID-19 presented the lowest survival probability by a considerable margin. It is possible that this effect is observed partly due to a more susceptible population within this group (e.g. higher number of comorbidities), or that the treatment was prescribed after the progression of the disease. Still, we would not recommend the use of this specific combination since it showed the worst survival rate by a great margin, even in those patients without comorbidities, as well as in the younger population. All the other combinations showed much more beneficial outcomes. Surprisingly the use of penicillin alone showed one of the best survival chances for COVID-19 patients in our study, we have not a straightforward explanation for this fact other than the possible prevention of pneumonia which was one of the main complications leading to death.

Acknowledgements

Competing interests. GGA, CAA and ALP declare to work at Amphora Health. ALP declares to hold shares at Amphora Health. CDB is on the scientific advisory boards of AncestryDNA, ArcBio LLC, Etalon DX, Liberty Biosecurity, Personalis, EdenRoc Sciences LLC. CDB and SMG declare to work at Galatea Bio. GGA and ALP are contractors at Galatea Bio. CDB declares to hold shares at Galatea Bio. The remaining authors declare that there is no conflict of interest regarding the publication of this article.

Contributions. ALP did the conceptualization. SGG and GGA did the data curation. GGA, CAA, AGG, SGG, GGA and ALP performed the formal analysis. AGG, CAA and GGA make the pertinent investigations. ALP designed the methodology and managed the project. APO, MFRM, MGA, KLL, TOC, NOG, SMG and CDB validate the results. GGA, AGG, SMG, CAA, and ALP drafted the manuscript. All the authors contributed critically, read, revised and approved the final version.

Funding. Research reported in this publication was partially supported via institutional funds from each participant institution. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Ethics approval. This study was approved by the Ethics and Research Committees from the Mexican Institute of Social Security (IMSS), which are certified as Institutional Review Board (IRB) in accordance with the Mexican regulation, under protocol numbers R-2021-1912-014, R-2020-785-058. Since, this was a retrospective study and the author SGG carried out the anonymization of data, the IRB waived all need for consent for this study.

Data Availability. The data that supports the findings of this study is available for research purposes upon written request, which will be reviewed on a case-by-case basis by IMSS IRB given the submission of a research protocol.

References

1. Yang A, Qiu Q, Kong X, Sun Y, Chen T, Zuo Y, et al. Clinical and Epidemiological Characteristics of COVID-19 Patients in Chongqing China. Front Public Health. 2020 May 29;8:244.
2. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar 12;579(7798):270–3.
3. La Torre G, Massetti AP, Antonelli G, Fimiani C, Fantini M, Marte M, et al. Anosmia and Ageusia as Predictive Signs of COVID-19 in Healthcare Workers in Italy: A Prospective Case-Control Study. J Clin Med. 2020 Sep 4;9(9):2870.
4. Lopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021 Dec;11(1):16144.
5. Centers for Disease Control and Prevention. Coronavirus Disease 2019 (COVID-19). Information for people who are at higher Risk for Severe Illness. 2020.
6. CDC COVID-19 Response Team, CDC COVID-19 Response Team, Chow N, Fleming-Dutra K, Gierke R, Hall A, et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020 Apr 3;69(13):382–6.
7. CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek S, Boundy E, Bowen V, Chow N, et al. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020 Mar 27;69(12):343–6.
8. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020 Mar 17;323(11):1061.
9. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul;56(1):105949.

10. World Health Organization. World Health Organization, WHO (2019), 2019-nCoV outbreak is an emergency of international concern. Available http://www.euro.who.int/en/health-topics/health-emergencies/international-health-regulations/news/news/2020/2/2019-ncov-outbreak-is-an-emergency-of-international-concern.
11. Centers for Disease Control and Prevention (CDC). Emerging SARS-CoV-2 Variants. Updated Jan 2 2021. 2021 Jan.
12. World Health Organization. World Health Organization. COVID-19 Dashboard [Internet]. [cited 2022 Aug 5]. Available from: https://covid19.who.int/
13. Johns Hopkins University. Mortality in the most affected countries [Internet]. 2022 Aug [cited 2022 Aug 5]. Available from: https://coronavirus.jhu.edu/data/mortality
14. Secretaría de Relaciones Exteriores. El Plan Nacional de Vacunación se llevará a cabo en tiempo y forma, de acuerdo a los periodos programados: Ebrard [Internet]. 2020 [cited 2022 Aug 5]. Available from: https://www.gob.mx/sre/articulos/el-plan-nacional-de-vacunacion-se-llevara-a-cabo-en-tiempo-y-forma-de-acuerdo-a-los-periodos-programados-ebrard-260227
15. Instituto Mexicano del Seguro Social. Algoritmos terapéuticos para el manejo del COVID-19 (07 Abril 2020). 2020.
16. Instituto Mexicano del Seguro Social. Algoritmo terapéutico para el manejo del COVID-19 (25 Junio 2020). 2020.
17. Instituto Mexicano del Seguro Social. Algoritmo terapéutico para el manejo del COVID-19 (25 Septiembre 2020). 2020.
18. Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517–25.
19. The RECOVERY Collaborative Group. Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med. 2020 Nov 19;383(21):2030–40.
20. Cavalcanti AB, Zampieri FG, Rosa RG, Azevedo LCP, Veiga VC, Avezum A, et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19. N Engl J Med. 2020 Nov 19;383(21):2041–52.
21. Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV, Vallone MG, Vázquez C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med. 2021 Feb 18;384(7):619–29.
22. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2021 Jan 21;384(3):229–37.

23. Aziz M, Brenner M, Wang P. Therapeutic Potential of B-1a Cells in COVID-19. Shock. 2020 Nov;54(5):586–94.
24. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet. 2007 Oct;370(9596):1453–7.
25. McCaw ZR, Tian L, Vassy JL, Ritchie CS, Lee CC, Kim DH, et al. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19. Ann Intern Med. 2020 Oct 20;173(8):632–7.
26. Gray RJ. A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk. Ann Stat. 1988 Sep;16(3):1141–54.
27. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc. 1999 Jun;94(446):496–509.
28. Brier GW. VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY. Mon Weather Rev. 1950 Jan;78(1):1–3.
29. World Health Organization. Director-General's opening remarks at the media briefing on COVID-19. 2020 Mar.
30. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020 May;55(5):2000547.
31. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May 26;323(20):2052–9.
32. Calixto-Calderón B, Vázquez-González MF, Martínez Peláez R, Bermeo-Escalona JR, García V, Mena LJ, et al. Pre-existing comorbidity, the highest risk factor for poor prognosis of COVID-19 among the Mexican population. Nova Sci [Internet]. 2021 Apr 9 [cited 2022 Aug 5];13. Available from: http://novascientia.delasalle.edu.mx/ojs/index.php/Nova/article/view/2823
33. Salinas-Escudero G, Carrillo-Vega MF, Granados-García V, Martínez-Valverde S, Toledano-Toledano F, Garduño-Espinosa J. A survival analysis of COVID-19 in the Mexican population. BMC Public Health. 2020 Dec;20(1):1616.
34. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020 May;8(5):475–81.
35. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA [Internet]. 2020 Mar 23 [cited 2022 Aug 5]; Available from:

https://jamanetwork.com/journals/jama/fullarticle/2763667

36. Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol Off J Ger Card Soc. 2020 May;109(5):531–8.
37. Franceschi C, Garagnani P, Parini P, Giuliani C, Santoro A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat Rev Endocrinol. 2018 Oct;14(10):576–90.
38. Singh MV, Chapleau MW, Harwani SC, Abboud FM. The immune system and hypertension. Immunol Res. 2014 Aug;59(1–3):243–53.
39. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415–45.
40. Morgan OW, Bramley A, Fowlkes A, Freedman DS, Taylor TH, Gargiullo P, et al. Morbid obesity as a risk factor for hospitalization and death due to 2009 pandemic influenza A(H1N1) disease. PloS One. 2010 Mar 15;5(3):e9694.
41. Food and Drug Administration. Actualización sobre el coronavirus (COVID-19): La FDA autoriza un antiviral oral adicional para el tratamiento contra el covid-19 en ciertos Adultos [Internet]. 2021 [cited 2022 Aug 5]. Available from: https://www.fda.gov/news-events/press-announcements/actualizacion-sobre-el-coronavirus-covid-19-la-fda-autoriza-un-antiviral-oral-adicional-para-el
42. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19 [Internet]. 2021 [cited 2022 Aug 5]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19
43. Whittington MD, Pearson SD, Rind DM, Campbell JD. The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19. Value Health. 2022 May;25(5):744–50.
44. Liu R, Rizzo S, Whipple S, Pal N, Pineda AL, Lu M, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature. 2021 Apr;592(7855):629–33.
45. López-Pineda A, Rodríguez-Moran MF, Álvarez-Aguilar C, Fuentes Valle SM, Acosta-Rosales R, Bhatt AS, et al. Data mining of digitized health records in a resource-constrained setting reveals that timely immunophenotyping is associated with improved breast cancer outcomes. BMC Cancer. 2018 Dec;18(1):933.


Extraction (Read Data)
Transformation (Remove Duplicates, Recode)
Load (Save file and merge)
Stratification
AI, age, sex, obesity, diabetes, hypertension, pneumonia
Machine Learning: 10 fold cross-validation
Training
Test
Logistic Regression (LR)
Random Forest(RF)
Evaluation
AUC, BSS
Death or Recovery at 10, 20 and 30 days
Baseline Characteristics (Table1)
Treatment Patterns Analysis (UpsetPlot)
Survival Analysis
Competing Risk Analysis, Kaplan Meier, Cox Regression
Endpoints: Death, Recovery


A)
p-value
Dyspnea
Pneumonia
Renal problem
HVI
Cyanosis
Male
Immunosuppression
Cancer
Obesity
Liver disease
Diabetes
Irritability in children
Postration
Abdominal pain
Chest pain
Hypertension
Age
Arthralgias
Chills
Tuberculosis
Conjunctivitis
Diarrhea
Mialgias
Anosmia
Smoking
Cardiovaascular
Asthma
Coryza
COPD
Rinorrhea
<0.001 ***
0.016 *
<0.001 ***
<0.001 ***
0.13
0.896
<0.001 ***
<0.001 ***
<0.001 ***
<0.001 ***
<0.001 ***
0.004 **
<0.001 ***
<0.001 ***
<0.001 ***
<0.001 ***
0.002 **
0.212
<0.001 ***
<0.001 ***
0.097 *
<0.001 ***
0.144
<0.001 ***
<0.001 ***
0.003 **
0.006 **
<0.001 ***
0.002 **
<0.001 ***
0 1 2 3 4 5 6
Odds ratio


B)
p-value
Cephalosporins + NAIs
Cephalosporins
NAIs + Others
NAIs
Macrolides
Macrolides + NAIs
Penicilins + NAIs
Others
Penicilins
Fluoroquinolones
Adamantanes
0.652
<0.001 ***
<0.001 ***
0.769
<0.001 ***
0.015 *
<0.001 ***
<0.001 ***
<0.001 ***
0.205
0.085 *
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21
Odds ratio


Cumulative incidence functions
event
Death
Recovery
Adamantanes
Cephalosporins
Cephalosporins+NAIs
Fluoroquinolones
Macrolides
NAIs
NAIs+Others
Others
Penicilins
Unrecorded
Probability of an event
0.00
0.25
0.50
0.75
0
20
40
60
Days